1.15Open1.15Pre Close0 Volume190 Open Interest290.00Strike Price0.00Turnover49.26%IV14.67%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry1.15Extrinsic Value100Contract SizeAmericanOptions Type0.0519Delta0.0053Gamma597.44Leverage Ratio-0.1089Theta0.0033Rho30.98Eff Leverage0.0433Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet